Mirum Pharmaceuticals saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 87 to 91.
Here Are 3 Keys For Successful Stock Investing
This exclusive rating from Investor's Business Daily tracks price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the best stocks tend to have an RS Rating of at least 80 in the early stages of their moves.
The IBD 50 stock has climbed more than 5% past a 51.93 entry in a first-stage cup with handle, meaning it's now out of a proper buy zone. Look for the stock to create a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
The company showed 0% EPS growth in the latest quarterly report, while sales growth came in at 64%.
Mirum Pharmaceuticals holds the No. 8 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Rigel Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
